Moderna Bivalent Covid-19 Booster Shot Shows Encouraging Results Against Virus Strains
19 Abril 2022 - 8:50AM
Dow Jones News
By Chris Wack
Moderna Inc. said new clinical data on its Covid-19 booster
platform shows the vaccine is effective against mutations found in
the Beta variant of concern, several of which have been persistent
in more-recent variants of concern including Omicron.
The company said a 50 ug booster dose of mRNA-1273.211
demonstrated superiority against Beta, Delta and Omicron variants
of concern one month after administration.
Superiority continued six months after administration for Beta
and Omicron variants of concern, as well, it said.
A 50 ug booster dose of mRNA-1273.211 was generally well
tolerated with a reactogenicity profile comparable to a booster
dose of mRNA-1273 at the 50 ug dose level, it said.
Moderna said it is developing updated booster candidates to
address the continued evolution of the SARS-CoV-2 virus, including
monovalent and bivalent candidates targeting multiple variants of
concern. The company's primary focus has been on the bivalent
booster approach to maintain high neutralizing antibody titers
while improving breadth of immunity to variants, it said.
A 50 ug booster dose of mRNA-1273.211 met Moderna's objectives
for its modified, bivalent booster candidates, including
superiority immunogenicity criteria against variants of concern
when compared with its currently approved mRNA-1273 booster dose,
it said. A booster dose of mRNA-1273.211 demonstrated superiority
against the ancestral SARS-CoV-2 and the Beta, Delta and Omicron
variants one month after the booster dose, and superiority against
the ancestral SARS-CoV-2, Beta and Omicron six months compared with
the booster dose of mRNA-1273.
The mRNA-1273.211 booster candidate was generally well tolerated
in 300 study participants who received the 50 ug dose and 595
participants who received the 100 ug dose of mRNA-1273.211, Moderna
said.
The company said it expects initial data on booster candidate
mRNA-1273.214 in the second quarter to inform selection of its
candidate for the Northern Hemisphere fall 2022 booster.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 19, 2022 07:35 ET (11:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
